tbuckley/cabot-search huggingface dataset:
Prevalence, clinical characteristics and outcomes of heart failure patients with or without isolated or combined mitral and tricuspid regurgitation: An analysis from the <scp>ESC‐HFA</scp> Heart Failure Long‐Term Registry
Authors: Marianna Adamo, Ovidiu Chioncel, Lina Benson, Bahira Shahim, Maria G. Crespo‐Leiro, Stefan D. Anker, Andrew J.S. Coats, Gerasimos Filippatos, Mitja Lainscak, Theresa McDonagh, Alexander Mebazaa, Massimo F. Piepoli, Giuseppe M.C. Rosano, Frank Ruschitzka, Gianluigi Savarese, Petar Seferovic, Angiza Shahim, Bogdan A. Popescu, Bernard Iung, Maurizio Volterrani, Aldo P. Maggioni, Marco Metra, Lars H. Lund
Journal: European Journal of Heart Failure (2023)
Innumerable
Authors: Joseph Gascho
Journal: JAMA (2023)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Impact of a novel prognostic model on allogeneic hematopoietic stem cell transplantation outcomes in patients with<scp>CMML</scp>
Authors: Jian‐Ying Zhou, Song Wang, Hai‐Long Yuan, Ya‐Jing Xu, Xiao‐Bing Huang, Su‐Jun Gao, Yi‐Cheng Zhang, Fang Zhou, Yue Liu, Xian‐Min Song, Yu Cai, Xiao‐Liang Liu, Yi Luo, Lu‐Xin Yang, Jian‐Min Yang, Li‐Bing Wang, Yu‐Hua Li, Rui Huang, Shun‐Qing Wang, Ming Zhou, Yu‐Jun Dong, Qian Wang, Xi Zhang, Yi‐Mei Feng, Xin Du, Wei Ling, Han Zhu, Zun‐Min Zhu, Xiang‐Li Chen, Shi‐Yu Wang, Fan‐Kai Meng, Ke‐Hong Bi, Ning Huang, Ming Jiang, Ting Niu, Jie Ji, Ding‐Ming Wan, Zhi‐Lei Bian, Yi Chen, Li Liu, Xue‐Qian Yan, Xi Yang, Hai Yi, Xu‐Dong Wei, Xin Li, Qian Cheng, Cheng‐Lu Yuan, Wen Wang, Yu‐Hong Zhou, Bao‐Dong Ye, Jing Ding, Ye‐Jun Wu, Qiu‐Sha Huang, Xiao‐Lu Zhu, Yu‐Hong Chen, Yun He, Feng‐Rong Wang, Yuan‐Yuan Zhang, Xiao‐Dong Mo, Wei Han, Jing‐Zhi Wang, Yu Wang, Huan Chen, Xiang‐Yu Zhao, Ying‐Jun Chang, Kai‐Yan Liu, Xiao‐Jun Huang, Xiao‐Hui Zhang
Journal: American Journal of Hematology (2023)

Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic stem cell malignancy, and allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only curable treatment. The outcomes after transplant are influenced by both disease characteristics and patient comorbidities. To develop a novel prognostic model to predict the post-transplant survival of CMML patients, we identified risk factors by applying univariable and multivariable Cox proportional hazards regression to a derivation cohort. In multivariable analysis, advanced age (hazard ratio [HR] 3.583), leukocyte count (HR 3.499), anemia (HR 3.439), bone marrow blast cell count (HR 2.095), and no chronic graft versus host disease (cGVHD; HR 4.799) were independently associated with worse survival. A novel prognostic model termed ABLAG (Age, Blast, Leukocyte, Anemia, cGVHD) was developed and the points were assigned according to the regression equation. The patients were categorized into low risk (0-1), intermediate risk (2, 3), and high risk (4-6) three groups and the 3-year overall survival (OS) were 93.3% (95%CI, 61%-99%), 78.9% (95%CI, 60%-90%), and 51.6% (95%CI, 32%-68%; p < .001), respectively. In internal and external validation cohort, the area under the receiver operating characteristic (ROC) curves of the ABLAG model were 0.829 (95% CI, 0.776-0.902) and 0.749 (95% CI, 0.684-0.854). Compared with existing models designed for the nontransplant setting, calibration plots, and decision curve analysis showed that the ABLAG model revealed a high consistency between predicted and observed outcomes and patients could benefit from this model. In conclusion, combining disease and patient characteristic, the ABLAG model provides better survival stratification for CMML patients receiving allo-HSCT.
Distinct inflammatory Th17 subsets emerge in autoimmunity and infection
Authors: Ronald J. Bouch, Jing Zhang, Brandi C. Miller, Caroline J. Robbins, Timothy H. Mosher, Wencheng Li, Sergey A. Krupenko, Ravinder Nagpal, Jun Zhao, Richard S. Bloomfeld, Yong Lu, Mikhail A. Nikiforov, Qianqian Song, Zhiheng He
Journal: The Journal of Experimental Medicine (2023)

Th17 cells play a critical role in both tissue homeostasis and inflammation during clearance of infections as well as autoimmune and inflammatory disorders. Despite numerous efforts to distinguish the homeostatic and inflammatory roles of Th17 cells, the mechanism underlying the divergent functions of inflammatory Th17 cells remains poorly understood. In this study, we demonstrate that the inflammatory Th17 cells involved in autoimmune colitis and those activated during colitogenic infection are distinguishable populations characterized by their differential responses to the pharmacological molecule, clofazimine (CLF). Unlike existing Th17 inhibitors, CLF selectively inhibits proautoimmune Th17 cells while preserving the functional state of infection-elicited Th17 cells partially by reducing the enzyme ALDH1L2. Overall, our study identifies two distinct subsets within the inflammatory Th17 compartment with distinct regulatory mechanisms. Furthermore, we highlight the feasibility to develop disease-promoting Th17 selective inhibitor for treating autoimmune diseases.
International Mental Health
Journal: JAMA (2023)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The White House’s Strategic Plan to Address the Opioid Crisis
Authors: Barbara H. Chaiyachati, Emily Bosk, Davida M. Schiff
Journal: JAMA (2023)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Error in Text Wording and Incorrect Reference
Journal: JAMA (2023)

Jun Watanabe, MD, PhD; Kei Muro, MD, PhD; Kohei Shitara, MD, PhD; Kentaro Yamazaki, MD, PhD; Manabu Shiozawa, MD, PhD; Hisatsugu Ohori, MD, PhD; Atsuo Takashima, MD, PhD; Mitsuru Yokota, MD, PhD; Akitaka Makiyama, MD, PhD; Naoya Akazawa, MD; Hitoshi Ojima, MD, PhD; Yasuhiro Yuasa, MD, PhD; Keisuke Miwa, MD, PhD; Hirofumi Yasui, MD, PhD; Eiji Oki, MD, PhD; Takeo Sato, MD, PhD; Takeshi Naitoh, MD, PhD; Yoshito Komatsu, MD, PhD; Takeshi Kato, MD, PhD; Masamitsu Hihara, MS; Junpei Soeda, MD, PhD; Toshihiro Misumi, PhD; Kouji Yamamoto, PhD; Kiwamu Akagi, MD, PhD; Atsushi Ochiai, MD, PhD; Hiroyuki Uetake, MD, PhD; Katsuya Tsuchihara, MD, PhD; Takayuki Yoshino, MD, PhD
Transition From Mentored to Independent NIH Funding by Gender and Department
Authors: Mytien Nguyen, Aanya Panyadahundi, Christine Olagun-Samuel, Sarwat I. Chaudhry, Mayur M. Desai, Alan Dardik, Dowin Boatright
Journal: JAMA (2023)

This study uses National Institutes of Health RePORTER data for mentored K awards and R01-equivalent grants to all departments in US schools of medicine to characterize K-award distribution and K-to-R transition by gender and department between 1997 and 2021.
Brain macrophage development, diversity and dysregulation in health and disease
Authors: Aymeric Silvin, Jiawen Qian, Florent Ginhoux
Journal: Cellular and Molecular Immunology (2023)

Abstract Brain macrophages include microglia in the parenchyma, border-associated macrophages in the meningeal-choroid plexus-perivascular space, and monocyte-derived macrophages that infiltrate the brain under various disease conditions. The vast heterogeneity of these cells has been elucidated over the last decade using revolutionary multiomics technologies. As such, we can now start to define these various macrophage populations according to their ontogeny and their diverse functional programs during brain development, homeostasis and disease pathogenesis. In this review, we first outline the critical roles played by brain macrophages during development and healthy aging. We then discuss how brain macrophages might undergo reprogramming and contribute to neurodegenerative disorders, autoimmune diseases, and glioma. Finally, we speculate about the most recent and ongoing discoveries that are prompting translational attempts to leverage brain macrophages as prognostic markers or therapeutic targets for diseases that affect the brain.
Blood group A enhances SARS-CoV-2 infection
Authors: Shang-Chuen Wu, Connie M. Arthur, Hau-Ming Jan, Wilfredo F. Garcia-Beltran, Kashyap R. Patel, Matthew F. Rathgeber, Hans P. Verkerke, Narayanaiah Cheedarla, Ryan Philip Jajosky, Anu Paul, Andrew S. Neish, John D. Roback, Cassandra D. Josephson, Duane R. Wesemann, Daniel Kalman, Seth Rakoff-Nahoum, Richard D. Cummings, Sean R. Stowell
Journal: Blood (2023)
Reduced <scp>miR</scp>‐223 increases blood neutrophil extracellular trap and promotes skin inflammation in atopic dermatitis
Authors: Tsai‐Ling Liao, Chi‐Chien Lin, Yi‐Hsing Chen, Kuo‐Tung Tang
Journal: Allergy (2023)

The data that support the findings of this study are available from the corresponding author upon reasonable request. Appendix S1. Figure S1. Figure S2. Figure S3. Table S1. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
Short‐course subcutaneous treatment with PQ Grass strongly improves symptom and medication scores in grass allergy
Authors: P. J. de Kam, S. Zielen, J. A. Bernstein, U. Berger, M. Berger, M. Cuevas, D. Cypcar, A. Fuhr‐Horst, W. A. Greisner, M. Jandl, S. Laßmann, M. Worm, J. Matz, E. Sher, C. Smith, G. C. Steven, R. Mösges, M. H. Shamji, L. DuBuske, F. Borghese, K. Oluwayi, T. Zwingers, M. Seybold, O. Armfield, M. D. Heath, S. J. Hewings, M. F. Kramer, M. A. Skinner
Journal: Allergy (2023)

A modified grass allergen subcutaneous immunotherapy (SCIT) product with MicroCrystalline Tyrosine and monophosphoryl lipid-A as an adjuvant system (Grass MATA MPL [PQ Grass]) is being developed as short-course treatment of grass-pollen allergic rhinitis (SAR) and/or rhinoconjunctivitis. We sought to evaluate the combined symptom and medication score (CSMS) of the optimized cumulative dose of 27,600 standardized units (SU) PQ Grass in a field setting prior to embarking on a pivotal Phase III trial.
Janus Kinase Inhibitors for Alopecia Areata
Authors: Ming Liu, Ya Gao, Yuan Yuan, Kelu Yang, Caiyi Shen, Jiancheng Wang, Jinhui Tian
Journal: JAMA Network Open (2023)

Importance Alopecia areata (AA) is a common chronic tissue-specific autoimmune disease. Several studies have reported outcomes of Janus kinase (JAK) inhibitors for treating AA, but limited evidence has emerged. Objective To evaluate the effectiveness and safety associated with JAK inhibitors for AA. Data Sources MEDLINE, Embase, and CENTRAL (Cochrane Central Register of Controlled Trials) were searched from inception until August 2022. Study Selection Only randomized clinical trials (RCTs) were included. Pairs of reviewers independently and in duplicate selected the studies. Data Extraction and Synthesis Hartung-Knapp-Sidik-Jonkman random-effects models were used for meta-analysis. Certainty of evidence was evaluated using the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) approach. This study is reported according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guideline. Main Outcomes and Measures The primary outcomes of interest were (1) proportion of patients who achieved 30%, 50%, and 90% improvement in Severity of Alopecia Tool (SALT) score from baseline, (2) change from baseline SALT score, and (3) treatment-related adverse event (AE). Results Seven RCTs with 1710 patients (1083 females [63.3%]; mean [SD] age range, 36.3 [10.4] to 69.7 [16.2] years) were eligible and included in the study. JAK inhibitors were associated with more patients achieving 50% improvement (odds ratio [OR], 5.28 [95% CI, 1.69-16.46]; GRADE assessment: low certainty) and 90% improvement (OR, 8.15 [95% CI, 4.42-15.03]; GRADE assessment: low certainty) in SALT score from baseline compared with placebo. JAK inhibitors were associated with more lowered SALT scores from the baseline compared with placebo (mean difference [MD], –34.52 [95% CI, −37.80 to −31.24]; GRADE assessment: moderate certainty), and JAK inhibitors were not associated with more treatment-related AEs (relative risk [RR], 1.25 [95% CI, 1.00-1.57]; GRADE assessment: high certainty) compared with placebo. High certainty of evidence showed that JAK inhibitors may not be associated with more severe AEs compared with placebo (RR, 0.77; 95% CI, 0.41-1.43). The subgroup analysis showed that oral JAK inhibitors were more efficient than placebo (change from baseline SALT scores: MD, –36.80; 95% CI, −39.57 to −34.02), and no difference was found between external JAK inhibitors and placebo (change from baseline SALT scores: MD, –0.40; 95% CI, −11.30 to 10.50). Conclusions and Relevance Results of this systematic review and meta-analysis suggest that JAK inhibitors, compared with placebo, were associated with hair regrowth and that the outcome of oral JAK inhibitors was better than the external route of administration. Although the safety and tolerability of JAK inhibitors were acceptable, longer RCTs are needed to further assess the effectiveness and safety of these treatments for AA.
Neglected gut microbiome: interactions of the non-bacterial gut microbiota with enteric pathogens
Authors: Kanchan Jaswal, Olivia A Todd, Judith Behnsen
Journal: Gut Microbes (2023)

A diverse array of commensal microorganisms inhabits the human intestinal tract. The most abundant and most studied members of this microbial community are undoubtedly bacteria. Their important role in gut physiology, defense against pathogens, and immune system education has been well documented over the last decades. However, the gut microbiome is not restricted to bacteria. It encompasses the entire breadth of microbial life: viruses, archaea, fungi, protists, and parasitic worms can also be found in the gut. While less studied than bacteria, their divergent but important roles during health and disease have become increasingly more appreciated. This review focuses on these understudied members of the gut microbiome. We will detail the composition and development of these microbial communities and will specifically highlight their functional interactions with enteric pathogens, such as species of the family
Prevalence of Iron Deficiency and Iron-Deficiency Anemia in US Females Aged 12-21 Years, 2003-2020
Authors: Angela C. Weyand, Alexander Chaitoff, Gary L. Freed, Michelle Sholzberg, Sung Won Choi, Patrick T. McGann
Journal: JAMA (2023)

This study examines prevalence of iron deficiency among females aged 12 to 21 years to inform future screening strategies for iron deficiency and iron-deficiency anemia.
Programmed T cells infiltration into lung metastases with harnessing dendritic cells in cancer immunotherapies by catalytic antigen-capture sponges
Authors: Min-Ren Chiang, Wei-Ting Shen, Pin-Xuan Huang, Kang-Li Wang, Wei-Han Weng, Chien-Wen Chang, Wen-Hsuan Chiang, Yu-Chen Liu, Shing-Jyh Chang, Shang-Hsiu Hu
Journal: Journal of Controlled Release (2023)
The White House’s Strategic Plan to Address the Opioid Crisis
Authors: Nastassja Michel, Julianne E. G. McGough, Rachel M. A. Linger
Journal: JAMA (2023)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Memory B cell development elicited by mRNA booster vaccinations in the elderly
Authors: Zijun Wang, Frauke Muecksch, Raphael Raspe, Frederik Johannsen, Martina Turroja, Marie Canis, Mohamed A. ElTanbouly, Gabriela S. Silva Santos, Brianna Johnson, Viren A. Baharani, Rachel Patejak, Kai-Hui Yao, Bennett J. Chirco, Katrina G. Millard, Irina Shimeliovich, Anna Gazumyan, Thiago Y. Oliveira, Paul D. Bieniasz, Theodora Hatziioannou, Marina Caskey, Michel C. Nussenzweig
Journal: The Journal of Experimental Medicine (2023)

Despite mRNA vaccination, elderly individuals remain especially vulnerable to severe consequences of SARS-CoV-2 infection. Here, we compare the memory B cell responses in a cohort of elderly and younger individuals who received mRNA booster vaccinations. Plasma neutralizing potency and breadth were similar between the two groups. By contrast, the absolute number of SARS-CoV-2–specific memory B cells was lower in the elderly. Antibody sequencing revealed that the SARS-CoV-2–specific elderly memory compartments were more clonal and less diverse. Notably, memory antibodies from the elderly preferentially targeted the ACE2-binding site on the RBD, while those from younger individuals targeted less accessible but more conserved epitopes. Nevertheless, individual memory antibodies elicited by booster vaccines in the elderly and younger individuals showed similar levels of neutralizing activity and breadth against SARS-CoV-2 variants. Thus, the relatively diminished protective effects of vaccination against serious disease in the elderly are associated with a smaller number of antigen-specific memory B cells that express altered antibody repertoires.